JavaScript is disabled for your browser. Some features of this site may not work without it.
Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (Affirm)